169 related articles for article (PubMed ID: 38683155)
61. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
62. High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Dunna NR; Kandula V; Girdhar A; Pudutha A; Hussain T; Bandaru S; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(16):7089-95. PubMed ID: 26514495
[TBL] [Abstract][Full Text] [Related]
63. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib.
Elisei R; Ciampi R; Matrone A; Prete A; Gambale C; Ramone T; Simeakis G; Materazzi G; Torregrossa L; Ugolini C; Romei C
J Clin Endocrinol Metab; 2022 Jul; 107(8):2195-2202. PubMed ID: 35616103
[TBL] [Abstract][Full Text] [Related]
64. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
[TBL] [Abstract][Full Text] [Related]
65. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
[TBL] [Abstract][Full Text] [Related]
66. [Systemic therapies for advanced thyroid cancer - an update].
Brandenburg T; Machlah YM; Führer-Sakel D
Dtsch Med Wochenschr; 2023 Nov; 148(22):1412-1418. PubMed ID: 37918424
[TBL] [Abstract][Full Text] [Related]
67. Management of hereditary medullary thyroid carcinoma.
Pappa T; Alevizaki M
Endocrine; 2016 Jul; 53(1):7-17. PubMed ID: 26839093
[TBL] [Abstract][Full Text] [Related]
68. A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
Wijewardene A; Bastard K; Wang B; Gild M; Luxford C; Gill A; Robinson B; Bullock M; Clifton-Bligh R
Thyroid; 2023 Jan; 33(1):119-125. PubMed ID: 36416226
[No Abstract] [Full Text] [Related]
69. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
[TBL] [Abstract][Full Text] [Related]
70. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
71. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
72. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
73. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
74. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
[TBL] [Abstract][Full Text] [Related]
75. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
Maciel LMZ; Magalhães PKR
Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
[TBL] [Abstract][Full Text] [Related]
76. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
[TBL] [Abstract][Full Text] [Related]
77. Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan.
Fukuda N; Tanizawa Y; Nakamura K; Okada Y; Segall G; Kiiskinen U; Fasnacht N; Sanderson I; Rider A; Lewis K
Future Oncol; 2023 May; 19(16):1125-1137. PubMed ID: 37278236
[TBL] [Abstract][Full Text] [Related]
78. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
79. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
80. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]